Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-18
2006-04-18
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S253010
Reexamination Certificate
active
07030124
ABSTRACT:
Methods for treatment of depression or other affective mood disorders, such as bipolar manic depression or seasonal affective disorder, are disclosed by administration to a subject suffering or susceptible to same, of therapeutically effective diarylpiperazine compounds as herein described.
REFERENCES:
patent: 5552404 (1996-09-01), Chang et al.
patent: 5574159 (1996-11-01), Chang et al.
patent: 5658908 (1997-08-01), Chang et al.
patent: 5681830 (1997-10-01), Chang et al.
patent: 5807858 (1998-09-01), Chang et al.
patent: 5854249 (1998-12-01), Chang et al.
patent: 5985880 (1999-11-01), Chang et al.
patent: 6046200 (2000-04-01), Tortella et al.
patent: 6200978 (2001-03-01), Maw et al.
patent: 6300332 (2001-10-01), Chang et al.
patent: 2002/0022624 (2002-02-01), Dinnell et al.
patent: 2002/0052007 (2002-05-01), Chang
patent: WO 02/094794 (2002-11-01), None
Broom et al. “Nonpeptidic opioid receptor agonists reduce immobility in the forced swim assay in rats.” Neurophychopharmacology 2002—vol. 26, No. 6, 744-755.
Cottney et al. “Synthesis of novel analogues of the delta opioid ligand SNC-80 using rem resin.” Bioorganic & Medicinal Chemistry 9 (1999) 1323-1328.
Lopez et al. “Exploring the structure—activity relationships of [1-(4-tert-butyl-3′-hydroxy)benzhydryl-4-benzylpiperazines] (SL-3111), a high affinity and selective opioid receptor nonpeptide agonist ligand.” J. Med. Chem.1999, 42, 5359-5368.
Calderon et al. “Probes for narcotic receptor mediated phenomena.” J. Med. Chem. 1997, 40, 695-704.
Comer et al. “Convulsive effects of systemic administration of the delta opioid agonist BW272U86 in mice.” The Journal of Phar. and Exp. Ther. vol. 267, No. 2, 888-895. 1993.
M. Scott Furness, et al., Probes for Narcotic Receptor-Mediated Phenomena. 271Synthesis and Pharmacological Evalution of Selective L-Opioid Receptor Agonists from 4-[(ã KR)-K-(2S,5R)-4-Substituted—,5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and Their Enantiomers, J. Med.Chem., 2000, 43, 3193-3196.
Chang Kwen-Jen
Gengo Peter J.
Pendergast William
Ardent Pharmaceuticals, Inc.
Hultquist Steven J.
Intellectual Property / Technology Law
Spivack Phyllis G.
LandOfFree
Method of treating depression with delta receptor agonist... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating depression with delta receptor agonist..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating depression with delta receptor agonist... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3567824